Harmonised E22 E22 – General Considerations for Patient Preference Studies Read More In Process E22 E22 – General Considerations for Patient Preference Studies Read More Pre-harmonisation E22 – General Considerations for Patient Preference Studies Read More
Harmonised E23 E23 – Considerations for the Use of Real-World Evidence (RWE) to Inform Regulatory Decision Making with a Focus on Effectiveness of Medicines Read More In Process E23 E23 – Considerations for the Use of Real-World Evidence (RWE) to Inform Regulatory Decision Making with a Focus on Effectiveness of Medicines Read More Pre-harmonisation E23 – Considerations for the Use of Real-World Evidence (RWE) to Inform Regulatory Decision Making with a Focus on Effectiveness of Medicines Read More
Harmonised M1 M1 – MedDRA Points to Consider Read More In Process M1 M1 – MedDRA Points to Consider Read More Pre-harmonisation M1 – MedDRA Points to Consider Read More
Harmonised M2 M2 – Electronic Standards for the Transfer of Regulatory Information Read More In Process M2 M2 – Electronic Standards for the Transfer of Regulatory Information Read More Pre-harmonisation M2 – Electronic Standards for the Transfer of Regulatory Information Read More
Harmonised M7(R3) M7(R3) – Maintenance of the Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities Read More In Process M7(R3) M7(R3) – Maintenance of the Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities Read More Pre-harmonisation M7(R3) – Maintenance of the Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities Read More
Harmonised M7 Addendum M7 Addendum – Risk Assessment and Control of Nitrosamine Impurities Read More In Process M7 Addendum M7 Addendum – Risk Assessment and Control of Nitrosamine Impurities Read More Pre-harmonisation M7 Addendum – Risk Assessment and Control of Nitrosamine Impurities Read More
Harmonised M13C M13C – Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Highly Variable Drugs, Narrow Therapeutic Index Drugs and Complex Study Designs Read More In Process M13C M13C – Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Highly Variable Drugs, Narrow Therapeutic Index Drugs and Complex Study Designs Read More Pre-harmonisation M13C – Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Highly Variable Drugs, Narrow Therapeutic Index Drugs and Complex Study Designs Read More
Harmonised M16 M16 – Structured Product Quality Submissions Read More In Process M16 M16 – Structured Product Quality Submissions Read More Pre-harmonisation M16 – Structured Product Quality Submissions Read More
